COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND

被引：0
作者：
Prasongsook, Naiyarat [1 ]
Jaruhathai, Sureerat [1 ]
Maoleekulpairoj, Savitree [1 ]
Sooksriwong, Chaoncin [1 ]
机构：
[1] Mahidol Univ, Fac Pharm, Bangkok 10700, Thailand
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
TK1; Cost-effectiveness; gefitinib; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1245 / S1246
页数：2
相关论文
共 50 条
[21]   Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada [J].
Ondhia, U. ;
Conter, H. ;
Owen, S. ;
Zhou, A. ;
Nam, J. ;
Singh, S. ;
Abdulla, A. ;
Chu, P. ;
Felizzi, F. ;
Sangha, R. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S928-S928
[22]   A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) [J].
Lange, Ansgar ;
Prenzler, Anne ;
Frank, Martin ;
Golpon, Heiko ;
Welte, Tobias ;
von der Schulenburg, J-Matthias .
BMC PULMONARY MEDICINE, 2014, 14
[23]   A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) [J].
Ansgar Lange ;
Anne Prenzler ;
Martin Frank ;
Heiko Golpon ;
Tobias Welte ;
J-Matthias von der Schulenburg .
BMC Pulmonary Medicine, 14
[24]   Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China [J].
Gu, Xiaohua ;
Zhang, Qiang ;
Chu, Yun-Bo ;
Zhao, Yi-Yang ;
Zhang, Yan-Jun ;
Kuo, David ;
Su, Betty ;
Wu, Bin .
LUNG CANCER, 2019, 127 :84-89
[25]   Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach [J].
Fabienne Englmeier ;
Annalen Bleckmann ;
Wolfgang Brückl ;
Frank Griesinger ;
Annette Fleitz ;
Klaus Nagels .
Journal of Cancer Research and Clinical Oncology, 2023, 149 :1495-1511
[26]   Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China [J].
Lu, Shun ;
Ye, Ming ;
Ding, Lieming ;
Tan, Fenlai ;
Fu, Jie ;
Wu, Bin .
ONCOTARGET, 2017, 8 (06) :9996-10006
[27]   Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach [J].
Englmeier, Fabienne ;
Bleckmann, Annalen ;
Brueckl, Wolfgang ;
Griesinger, Frank ;
Fleitz, Annette ;
Nagels, Klaus .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (04) :1495-1511
[28]   Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) [J].
Tiseo, Marcello ;
Andreoli, Roberta ;
Gelsomino, Francesco ;
Mozzoni, Paola ;
Azzoni, Cinzia ;
Bartolotti, Marco ;
Bortesi, Beatrice ;
Goldoni, Matteo ;
Silini, Enrico Maria ;
De Palma, Giuseppe ;
Mutti, Antonio ;
Ardizzoni, Andrea .
LUNG CANCER, 2014, 83 (02) :265-271
[29]   Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib [J].
Tsujino, Kazuyuki ;
Kawaguchi, Tomoya ;
Kubo, Akihito ;
Aono, Nana ;
Nakao, Keiko ;
Koh, Yasuhiro ;
Tachibana, Kazunobu ;
Isa, Shun-ichi ;
Takada, Minoru ;
Kurata, Takayasu .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (08) :994-1001
[30]   Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study [J].
Ivette F Emery ;
Chiara Battelli ;
Paul L Auclair ;
Kathleen Carrier ;
Daniel M Hayes .
BMC Cancer, 9
12345